Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the SEBI (LODR) Regulations, 2015, Ind-Swift has informed that the Board of Directors of the Company in its meeting held on 14th August, 2021 has considered and approved the following: Un-Audited Financial Results and Limited Review Report for the quarter ended 30th June, 2021. (Un-audited results and Limited review report enclosed as Annexure-I), Sale of Manufacturing Unit No. III & IV (‘Undertaking’) of the Company to ANG Lifestiences India. (Information required pursuant to Regulation 39 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure-II), Approval of Board’s Report and Corporate Governance Report along with their Annexures for the year ended 31st March, 2021, Approval of Notice of 35th Annual General Meeting of the Company to be held on Wednesday 29th September, 2021. Register of Members and Share transfer Books of Company shall remain closed from 25th September, 2021 to 29th September, 2021 for 35th Annual General Meeting of the Company and The Board has approved the appointment of Vishal Arora, Practising Company Secretary as Scrutinizer for the process of voting at 35th Annual General Meeting. The Board meeting commenced at 4.30 PM and concluded at 7.00 pm.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1830.20 |
Dr. Reddys Lab | 1183.00 |
Cipla | 1549.65 |
Lupin | 2094.65 |
Zydus Lifesciences | 887.70 |
View more.. |